Supriya Lifescience, an energetic prescription drugs components manufacturer, has constant the charge band at Rs 265-274 consistent with fairness proportion for its preliminary public difficulty establishing on December 16.

The provide closes on December 20. Anchor book, if any, will open for bidding on December 15.

Investors can bid for at the very least fifty four fairness stocks and in multiples of fifty four stocks thereafter. Retail buyers can bid for at the very least stocks really well worth Rs 14,796 for one lot, and their most funding could be Rs 1,92,348 for thirteen lots, as they’re allowed to make investments withinside the IPO as much as Rs 2 lakh.

The enterprise is making plans to mobilise Rs seven hundred crore thru its public provide. The difficulty includes a sparkling issuance of stocks really well worth Rs two hundred crore and an provide-for-sale of Rs 500 crore via way of means of promoter Satish Waman Wagh who holds 99.ninety eight percentage fairness shareholding in Supriya Lifescience.

Of the whole provide size, seventy five percentage is reserved for certified institutional buyers, 10 percentage for retail buyers, and the final 15 percentage for non-institutional buyers.

The enterprise will utilise the proceeds from sparkling difficulty for capital expenditure requirements, and repaying of debts, except standard company purposes.

The enterprise has area of interest product services of 38 energetic prescription drugs components (APIs) targeted on numerous healing segments which includes antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic, as of October 2021.